Antiangiogenic and Antitumor Therapy for Retinoblastoma with Hypoxia-Inducible Factor-1α siRNA and Celastrol Co-Delivery Nanomicelles
- PMID: 33422159
- DOI: 10.1166/jbn.2020.2983
Antiangiogenic and Antitumor Therapy for Retinoblastoma with Hypoxia-Inducible Factor-1α siRNA and Celastrol Co-Delivery Nanomicelles
Abstract
Retinoblastoma (RB) makes up about 3% of all childhood malignancies. Chemotherapy is commonly applied for RB treatment, while the clinical effectiveness varies significantly due to the cancer therapeutic resistances. Hypoxic tumor microenvironment, a hallmark of all tumors, is strongly associated with malignant progress and therapeutic resistances. The hypoxia mainly promotes the angiogenesis by upregulating pro-angiogenetic pathways. In this work, polymeric micelles are used as the carrier to deliver celastrol and siRNA to RB cells for achieving synergistic anti-tumor and antiangiogenesis effects. The micelle vectors have shown effective cellular internalization and release of loaded-celastrol and HIF-1 siRNA. The co-delivery system specifically and synergistically inhibits the expression of HIF-1α and VEGF in RB cells, suppresses the HIF-1α /VEGF/VEGFR signaling pathway, and impedes the proliferation, migration, and invasion of vascular endothelial cells. The polymer micellar carrier that co-delivers HIF-1α siRNA and celastrol is used for antiangiogenic and antitumor therapy of RB. Altogether, the results show that our polymeric micelle delivery system can be used to overcome barriers of drug resistance induced by angiogenesis and develop new drug/siRNA combinatory therapies.
Similar articles
-
Effectively suppressed angiogenesis-mediated retinoblastoma growth using celastrol nanomicelles.Drug Deliv. 2020 Dec;27(1):358-366. doi: 10.1080/10717544.2020.1730522. Drug Deliv. 2020. PMID: 32091275 Free PMC article.
-
Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.Mol Pharm. 2012 Oct 1;9(10):2863-74. doi: 10.1021/mp300193f. Epub 2012 Sep 4. Mol Pharm. 2012. PMID: 22924580
-
Knockdown of hypoxia-inducible factor-1 alpha reduces proliferation, induces apoptosis and attenuates the aggressive phenotype of retinoblastoma WERI-Rb-1 cells under hypoxic conditions.Ann Clin Lab Sci. 2014 Spring;44(2):134-44. Ann Clin Lab Sci. 2014. PMID: 24795051
-
Hypoxia inducible factor-1α/vascular endothelial growth factor signaling activation correlates with response to radiotherapy and its inhibition reduces hypoxia-induced angiogenesis in lung cancer.J Cell Biochem. 2018 Sep;119(9):7707-7718. doi: 10.1002/jcb.27120. Epub 2018 Jun 15. J Cell Biochem. 2018. PMID: 29904944
-
Advanced Technologies of Drug Delivery to the Posterior Eye Segment Targeting Angiogenesis and Ocular Cancer.Crit Rev Ther Drug Carrier Syst. 2024;41(1):85-124. doi: 10.1615/CritRevTherDrugCarrierSyst.2023045298. Crit Rev Ther Drug Carrier Syst. 2024. PMID: 37824419 Review.
Cited by
-
LncRNA NEAT1 promotes angiogenesis of retinoblastoma cells through regulation of the miR-106a/HIF-1α axis.Heliyon. 2024 Mar 9;10(6):e27653. doi: 10.1016/j.heliyon.2024.e27653. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38524558 Free PMC article.
-
Nanoparticle-based delivery systems as emerging therapy in retinoblastoma: recent advances, challenges and prospects.Nanoscale Adv. 2023 Aug 15;5(18):4628-4648. doi: 10.1039/d3na00462g. eCollection 2023 Sep 12. Nanoscale Adv. 2023. PMID: 37705787 Free PMC article. Review.
-
Recent Trends in anti-tumor mechanisms and molecular targets of celastrol.Int J Biol Sci. 2024 Oct 7;20(14):5510-5530. doi: 10.7150/ijbs.99592. eCollection 2024. Int J Biol Sci. 2024. PMID: 39494324 Free PMC article. Review.
-
Celastrol inhibits laser-induced choroidal neovascularization by decreasing VEGF induced proliferation and migration.Int J Ophthalmol. 2022 Aug 18;15(8):1221-1230. doi: 10.18240/ijo.2022.08.01. eCollection 2022. Int J Ophthalmol. 2022. PMID: 36017049 Free PMC article.
-
Auxiliary effect of trolox on coenzyme Q10 restricts angiogenesis and proliferation of retinoblastoma cells via the ERK/Akt pathway.Sci Rep. 2024 Nov 9;14(1):27309. doi: 10.1038/s41598-024-76135-0. Sci Rep. 2024. PMID: 39516493 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources